论文部分内容阅读
目的:探讨宫颈液基薄层细胞学(TCT)检查联合高危人乳头瘤病毒DNA(HC2-HPV-DNA)检测在子宫颈癌前病变筛查中的应用价值。方法:回顾性分析80例拟诊子宫颈癌前病变患者的资料,所有患者均经TCT及HC2-HPV-DNA检查并通过病理学确诊,评价两种方法联合检测诊断子宫颈癌前病变的临床价值。结果:HC2-HPV-DNA的阳性率随宫颈癌前病变的严重程度而增加,差异有统计学意义(P<0.05);TCT联合HC2-HPV-DNA能提高子宫颈癌前病变检测的敏感性、特异性、准确性。结论:联合应用HC2-HPV-DNA和TCT检测方法能增加宫颈癌前病变的检出率,有效预防宫颈癌的发生发展,并为筛查癌前病变提供简便方法。
Objective: To investigate the value of cervical cytology-based cytology (TCT) combined with high-risk human papillomavirus DNA (HC2-HPV-DNA) in the screening of cervical precancerous lesions. Methods: A retrospective analysis of 80 cases of suspected cervical precancerous lesions in patients with information, all patients by TCT and HC2-HPV-DNA examination and pathological diagnosis, evaluation of two methods combined detection of cervical precancerous lesions in clinical value. Results: The positive rate of HC2-HPV-DNA increased with the severity of cervical precancerous lesions, the difference was statistically significant (P <0.05); TCT combined with HC2-HPV-DNA could improve the sensitivity of cervical precancerous lesions , Specificity, accuracy. Conclusion: The combination of HC2-HPV-DNA and TCT can increase the detection rate of cervical precancerous lesions and effectively prevent the occurrence and development of cervical cancer, and provide a convenient method for screening precancerous lesions.